UCB is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system.
UCB integrates expertise in large, antibody-based molecules and small, chemically-derived molecules. UCB strategy aims at delivering innovative small and large molecule solutions to specialists for severe diseases in its chosen therapeutic areas.
Already the leader in epilepsy, UCB is committed to providing novel solutions for people with severe conditions such as Parkinson’s disease, rheumatoid arthritis, and restless legs syndrome.
The 51-hectare site of Braine-l’Alleud has a strategic role and sustains UCB’s pipeline innovation. Here the focus is on pilot and first-
year launch industrial activities of UCB’s new products.
Poste et missions :
2. Identify the steps during which environmental criteria could and should be integrated. Make a mapping of the decision flows that influence the environmental impacts of other teams (eg production, pilot, ect .
energy - consumable) related to laboratories activities, for example by participating in the realization of Green Life Cycle Assessment -
using internally developed methodology - to identify the major root causes. 2. Propose actions to reduce the environmental impacts of activities by, for example, researching good practices of "Green Laboratories" in the pharmaceutical industry or elsewhere.
3. Monitor and implement some of the identified improvement projects.